MNLO - メンロ―・セラピュ―ティクス (Menlo Therapeutics Inc.) メンロ―・セラピュ―ティクス



symbol MNLO
会社名 Menlo Therapeutics Inc (メンロ―・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 メンロ・セラピューティクス(Menlo Therapeutics Inc.)は生物医薬品会社である。同社はアトピー性皮膚炎、乾癬、掻痒症などの皮膚疾患に関連する痒みの治療用セロピタントの開発と製品化に注力する。同社はまた難治性慢性咳嗽治療剤としてのセロピタント剤の使用を評価する。セロピタント剤は小分子で高度に選択的なNK1-R拮抗剤である。同社は1日1回経口錠剤療法としてのセロピタントの開発を行う。同社はアトピー性皮膚炎に関連する掻痒症の第II相臨床試験を行う。   メンロ―・セラピュ―ティクスは米国のバイオ医薬品メ―カ―。臨床段階で、主に皮膚疾患に対する治療薬の開発・製品化に従事する。同社の候補薬はアトピ―性皮膚炎、乾癬、結節性痒疹などの皮膚疾患による掻痒や、難治性・慢性咳嗽の治療のためのニュ―ロキニン1(NK-1)受容体アンタゴニストなどを含む。本社所在地はカリフォルニア州レッドウッドシティ。   Menlo Therapeutics Inc. operates as biopharmaceutical company which is focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. The company was founded by Ed F. Schnipper in October, 2011 and is headquartered in Redwood City, CA.
本社所在地 200 Cardinal Way 2nd Floor Redwood City CA 94063 USA
代表者氏名 Steven L. Basta スティーブンL.バスタ
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 650-486-1416
設立年月日 40817
市場名 NASDAQ National Market System
ipoyear 2018年
EBITDA EBITDA(百万ドル) -40.19600
終値(lastsale) 6.14
時価総額(marketcap) 141084907.72
時価総額 時価総額(百万ドル) 129.82570
売上高 売上高(百万ドル) 14.32400
企業価値(EV) 企業価値(EV)(百万ドル) -23.92930
当期純利益 当期純利益(百万ドル) -31.45300
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Menlo Therapeutics Inc revenues increased from $898K to $10.6M. Net loss increased 81% to $21M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase from $10.1M to $26.5M (expense) General and administrative increase from $2M to $5M (expense).



   Menlo Therapeutics Announces Completion of Corporate Name Change to VYNE Therapeutics  2020/09/08 12:01:00 PR Newswire
BRIDGEWATER, N.J., Sept. 8, 2020 /PRNewswire/ -- VYNE Therapeutics Inc. (Nasdaq: VYNE) ("VYNE" or the "Company") today completed its previously announced corporate name change from Menlo Therapeutics Inc. to VYNE Therapeutics Inc. and the change of its ticker symbol from "MNLO" to "VYNE"….
   This Analyst Thinks Menlo (MNLO) Stock Is Poised for Growth  2020/06/02 16:40:18 Yahoo Finance
2020 has been kind to small-cap biotechs. Some have spiked upwards dramatically this year, mostly on the hope of finding solutions to COVID-19, be it a treatment or vaccine. Those who haven’t gotten in on the action yet still yearn to join the fray, might justifiably feel a sense of apprehension. An
   Menlo Therapeutics (MNLO) Catches Eye: Stock Jumps 7.1%  2020/05/27 12:43:00 Zacks Investment Research
Menlo Therapeutics (MNLO) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
   Menlo Therapeutics Inc (MNLO) Reports Q1 Loss, Lags Revenue Estimates  2020/05/11 13:05:03 Zacks Investment Research
Menlo Therapeutics Inc (MNLO) delivered earnings and revenue surprises of -90.00% and -20.64%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   Menlo Therapeutics Inc. (MNLO) Shares March Higher, Can It Continue?  2020/05/06 13:56:52 Zacks Investment Research
As of late, it has definitely been a great time to be an investor in Menlo Therapeutics Inc. (MNLO).

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 メンロ―・セラピュ―ティクス MNLO Menlo Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)